Article (Author postprint) (165 Kb) - Limited access to UNIGE
Other version: http://www.nature.com/nrrheum/journal/v4/n11/full/ncprheum0900.html
Is tocilizumab a good therapeutic option for RA and systemic-onset juvenile idiopathic arthritis?
|Published in||Nature Reviews Rheumatology. 2008, vol. 4, no. 11, p. 572-3|
|Abstract||Interleukin (IL)-6 is a pleiotropic cytokine that has a major role in inflammatory diseases. The results of two recently published clinical trials that used different study designs demonstrated that tocilizumab, a humanized monoclonal antibody that targets the binding of IL-6 to its receptor, improved the clinical and biological signs of disease activity in both rheumatoid arthritis and systemic-onset juvenile idiopathic arthritis. Adverse events included a higher risk of infections, transient elevation of liver aminotransferases, higher cholesterol levels, and a few allergic reactions. Future studies should investigate the long-term efficacy (clinical and structural) and safety of tocilizumab, including its effect on lipid levels.|
|Keywords||Clinical trials — Interleukin-6 — Rheumatoid arthritis — Systemic-onset juvenile idiopathic arthritis — Tocilizumab|
|Research group||Mécanisme de l'inflammation articulaire (44)|
|GABAY, Cem. Is tocilizumab a good therapeutic option for RA and systemic-onset juvenile idiopathic arthritis?. In: Nature Reviews Rheumatology, 2008, vol. 4, n° 11, p. 572-3. doi: 10.1038/ncprheum0900 https://archive-ouverte.unige.ch/unige:1688|